China Bladder Cancer Market Trends, Research Report, Growth, Opportunities, Forecast 2022-2028
China
bladder cancer market is estimated to grow modestly at a CAGR of around 10.1%
during the forecast period. The country has a strong healthcare industry and is
continuously developing medical facilities and research centers to improve the
industry further. Bladder cancer is one of the major cancers diagnosed in the
elderly population of the country. The growing prevalence of bladder cancer in
the country is attributed to growth in the aging population and a rapid
increase in the number of smokers. Cancer is one of the leading causes of
mortality in China. According to WHO, China has reported a total of 82,270 new
cases of bladder cancer in 2018 out of which 38,208 cases resulted in
mortality. As per the organization, China accounts for 222,292 bladder cancer
patients in the last 5 years. Due to increasing industrialization in the
country, harmful chemicals are being ejected into the atmosphere and chemical
exposure is one of the major causes of bladder cancer. Therefore, with rapid
industrialization in the country, China is estimated to contribute
substantially to the global bladder cancer market during the forecast period.
A full report of China Bladder Cancer Market is
available at: https://www.omrglobal.com/industry-reports/china-bladder-cancer-market
China
bladder cancer market is segmented into cancer type, diagnosis, and treatment.
Based on cancer type, the market is segmented into transitional cell bladder
cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and
other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the
market is segmented into cystoscopy, biopsy, urinalysis, urine cytology,
intravenous pyelogram (IVP), and others. Based on treatment, the market is
segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and
other treatment which include targeted therapy.
To learn more about this report request a sample
copy @ https://www.omrglobal.com/request-sample/china-bladder-cancer-market
The
companies which are contributing to the growth of China bladder cancer market
include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co.,
GlaxoSmithKline PLC, and Pfizer, Inc. The market players are considerably
contributing to the market growth by the adoption of various strategies including
new product launch, merger, and acquisition, collaborations with government,
funding to the start-ups, and technological advancements to stay competitive in
the market.
China Bladder Cancer Market- Segmentation
By
Cancer type
·
Transitional Cell Bladder Cancer/ Urothelial
Carcinoma
·
Squamous Cell Bladder Cancer
·
Adenocarcinoma
·
Other Rare Types (Sarcomas, Carcinoma in Situ)
By
Diagnosis Method
·
Cystoscopy
·
Biopsy
·
Urinalysis
·
Urine Cytology
·
Intravenous Pyelogram (Ivp)
·
Other
By
Therapy
·
Chemotherapy
·
Immunotherapy
·
Radiation Therapy
·
Surgery
·
Other
Company Profiles
·
Astellas Pharma
Inc.
·
AstraZeneca PLC
·
Bayer AG
·
Bristol-Myers
Squibb Co.
·
Eli Lilly and Co.
·
F. Hoffmann-La
Roche Ltd.
·
GlaxoSmithKline Plc
·
Johnson &
Johnson Services, Inc.
·
Merck & Co.,
Inc.
·
Pfizer Inc.
·
Spectrum
Pharmaceuticals, Inc.
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more
than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and
after purchasing your report.
About Orion Market Research
Orion
Market Research (OMR) is a market research and consulting company known for its
crisp and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services.
Media Contact:
Contact
Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no:
+91 780-304-0404
Company
Name: Orion Market Research
0 Comments